Stem cell trial for rare bleeding disorder pulled before it began

NCT ID NCT06813157

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test whether infusions of mesenchymal stem cells could safely help people with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial was withdrawn before enrolling any participants, so no results are available. It would have given five stem cell infusions over several weeks and tracked platelet counts and bleeding for a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mesenchymal stem cells (MSCs)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dongguan Taixin Hospital

    Guangdong, Guangdong, 523125, China